Sherwood, Matthew
Bliden, Kevin P.
Ilkhanoff, Leonard
Venkataraman, Ganesh
Strickberger, Adam
Yazdani, Sharam
McSwain, Robert
Rashid, Haroon
Navarese, Eliano P.
Plummer, Tracy
Batchelor, Wayne
Chaudhary, Rahul
Tantry, Udaya S.
Gurbel, Paul A. http://orcid.org/0000-0002-5461-568X
Clinical trials referenced in this document:
Documents that mention this clinical trial
Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case–control study
https://doi.org/10.1007/s11239-020-02205-5
Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory
https://doi.org/10.1007/s11239-024-02953-8
Funding for this research was provided by:
Boston Scientific Corporation
Article History
First Online: 29 June 2020
Compliance with ethical standards
:
: Dr. Gurbel receives honoraria for lectures, consultations, including service on speakers’ bureaus from Bayer, Merck, Janssen, Medicure, and World Medical; receiving grants from the National Institutes of Health, Janssen, Merck, Bayer, Haemonetics, Instrumentation Labs, and Amgen. Dr. Gurbel is holding stock or stock options in Merck, Medtronic, and Pfizer; and holding patents in the area of personalized antiplatelet therapy and interventional cardiology. Dr. Sherwood receives honoraria from Medtronic. Dr. Navarese reports honoraria and payment for lectures from Astra Zeneca, Daiichi Sankyo/Lilly, Sanofi-Regeneron and Amgen; and receipt of grants from Amgen. Dr. Batchelor reports honoraria from Boston Scientific Corporation. Other authors report no disclosures.